Foghorn Therapeutics (FHTX) Shares Outstanding (Weighted Average) (2019 - 2026)

Foghorn Therapeutics' Shares Outstanding (Weighted Average) history runs 8 years deep, the most recent figure standing at $69.5 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 10.65% year-over-year to $69.5 million; the TTM figure through Mar 2026 stood at $69.5 million (up 10.65% YoY), while the FY2025 annual figure was $63.0 million, up 14.72% from the prior year.
• Shares Outstanding (Weighted Average) was $69.5 million for Q1 2026 at Foghorn Therapeutics, up from $63.0 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $69.5 million in Q1 2026 to a low of $41.4 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $50.7 million across 5 years, with a median of $42.4 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Weighted Average) soared 48.96% in 2024, then increased 0.56% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $41.6 million in 2022, then gained by 0.92% to $42.0 million in 2023, then surged by 30.79% to $54.9 million in 2024, then increased by 14.72% to $63.0 million in 2025, then advanced by 10.41% to $69.5 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $69.5 million (Q1 2026), $63.0 million (Q4 2025), and $63.0 million (Q3 2025), per Business Quant data.